EGA adopts disclosure requirements for the generic, biosimilar and value added medicines industry

EGA members unanimously adopted disclosure rules for the generic, biosimilar and value added medicines industry.

This will form an integral part of the EGA’s Code of Conduct that was adopted one year ago, available here.

The new chapter provides a framework to disclose support for patient organisations, healthcare professionals (HCPs) such as meetings and hospitality or educational support, as well as contributions to healthcare organisations (HCOs). EGA members will have one year to implement the disclosure requirements as they will start recording the data in January 2017 to publicly disclose in 2018.

“We are proud that the European generic, biosimilar and value added medicines industry has taken another bold step to build on its existing Code of Conduct. Disclosure enables the industry, healthcare professionals and patient organisations to jointly promote shared values of transparency, integrity, accountability and collaboration”, stated EGA President Jacek Glinka.